AR037356A1 - Forma de dosificacion oral de una prodroga de sulfonamida - Google Patents
Forma de dosificacion oral de una prodroga de sulfonamidaInfo
- Publication number
- AR037356A1 AR037356A1 ARP020104341A ARP020104341A AR037356A1 AR 037356 A1 AR037356 A1 AR 037356A1 AR P020104341 A ARP020104341 A AR P020104341A AR P020104341 A ARP020104341 A AR P020104341A AR 037356 A1 AR037356 A1 AR 037356A1
- Authority
- AR
- Argentina
- Prior art keywords
- prodrug
- solution
- composition
- parecoxib
- inhibit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica que está sustancialmente libre de agua, que comprende al menos una unidad de dosificación de administración oral que comprende una cantidad efectiva para el uso terapéutico de una prodroga de sulfonamida y, cuando la prodroga se degrada fácilmente ex vivo, tiene medios para inhibir tal degradación antes de la administración oral. Por ejemplo, la prodroga es parecoxib o una sal del mismo soluble en agua, y la composición tiene medios para inhibir la conversión del parecoxib en valdecoxib. Un método para tratar o prevenir un trastorno mediado por COX-2 analgesia en un sujeto, que comprende (a), disolver al menos una unidad de dosificación de tal composición en un vehículo acuoso aceptable para el uso farmacéutico para formar una solución, y (b) administrar por vía oral la solución al sujeto antes de que precipite sustancialmente materia insoluble en la solución.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35059601P | 2001-11-13 | 2001-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037356A1 true AR037356A1 (es) | 2004-11-03 |
Family
ID=23377399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104341A AR037356A1 (es) | 2001-11-13 | 2002-11-12 | Forma de dosificacion oral de una prodroga de sulfonamida |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20030100595A1 (es) |
| EP (1) | EP1446118B1 (es) |
| JP (1) | JP2005509002A (es) |
| KR (1) | KR20050044459A (es) |
| CN (1) | CN1615135A (es) |
| AR (1) | AR037356A1 (es) |
| AT (1) | ATE383156T1 (es) |
| BR (1) | BR0214081A (es) |
| CA (1) | CA2466504A1 (es) |
| CO (1) | CO5580744A2 (es) |
| DE (1) | DE60224558T2 (es) |
| ES (1) | ES2297032T3 (es) |
| IL (1) | IL161991A0 (es) |
| MX (1) | MXPA04004476A (es) |
| NO (1) | NO20042440L (es) |
| PL (1) | PL369962A1 (es) |
| RU (1) | RU2004114552A (es) |
| TW (1) | TW200300680A (es) |
| WO (1) | WO2003041705A1 (es) |
| ZA (1) | ZA200403328B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785640B2 (en) * | 2004-01-16 | 2010-08-31 | Amerilab Technologies, Inc. | Effervescent composition including cranberry extract |
| LT2801354T (lt) | 2004-10-08 | 2017-06-26 | Forward Pharma A/S | Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį |
| US7964223B2 (en) * | 2005-09-27 | 2011-06-21 | University Of Kentucky Research Foundation | Berry preparations and extracts |
| WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| US20100047371A1 (en) * | 2006-08-29 | 2010-02-25 | Mumper Russell J | Compositions and methods for oral cancer chemoprevention using berry preparations and extracts |
| EP1902708A1 (de) | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
| ES2377426T3 (es) * | 2007-10-12 | 2012-03-27 | Astrazeneca Ab | Composición de zibotentán que contiene manitol y celulosa microcristalina |
| US8906420B2 (en) | 2009-01-09 | 2014-12-09 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| JP6102120B2 (ja) * | 2012-08-16 | 2017-03-29 | ニプロ株式会社 | 医薬製剤およびその製造方法 |
| CN104771370B (zh) * | 2014-01-14 | 2020-07-24 | 南京圣和药业股份有限公司 | 帕瑞昔布钠冻干粉针剂及其制备方法 |
| CN104965041B (zh) * | 2015-06-11 | 2016-06-29 | 成都克莱蒙医药科技有限公司 | 一种帕瑞昔布钠异构体的高效液相色谱检测方法 |
| CN106074399B (zh) * | 2016-06-21 | 2018-11-02 | 马鞍山丰原制药有限公司 | 一种帕瑞昔布钠冻干制剂及其制备方法 |
| CN112409283A (zh) * | 2020-11-24 | 2021-02-26 | 苏州璞正医药有限公司 | 一种帕瑞昔布衍生物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995013794A1 (fr) * | 1993-11-18 | 1995-05-26 | Nippon Shinyaku Co., Ltd. | Procede pour produire une composition de medicament stable, et preparation pharmaceutique |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| EP0892791B1 (en) * | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
| SE9703693D0 (sv) * | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
| US6323226B1 (en) * | 1999-10-19 | 2001-11-27 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
| JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
| MY127898A (en) * | 1999-12-22 | 2006-12-29 | Pharmacia Corp | Dual-release compositions of a cyclooxygenase-2 inhibitor |
| US6403830B2 (en) * | 2000-03-24 | 2002-06-11 | Pharmacia Corporation | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
| US6306842B1 (en) * | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
| JP2004503588A (ja) * | 2000-07-13 | 2004-02-05 | ファルマシア・コーポレーション | 全身性疼痛および頭痛に対する選択的シクロオキシゲナーゼ−２阻害薬および血管調節化合物 |
| MY137736A (en) * | 2001-04-03 | 2009-03-31 | Pharmacia Corp | Reconstitutable parenteral composition |
-
2002
- 2002-11-12 RU RU2004114552/14A patent/RU2004114552A/ru not_active Application Discontinuation
- 2002-11-12 DE DE60224558T patent/DE60224558T2/de not_active Expired - Fee Related
- 2002-11-12 PL PL02369962A patent/PL369962A1/xx not_active Application Discontinuation
- 2002-11-12 US US10/292,682 patent/US20030100595A1/en not_active Abandoned
- 2002-11-12 EP EP02789593A patent/EP1446118B1/en not_active Expired - Lifetime
- 2002-11-12 CN CNA028270843A patent/CN1615135A/zh active Pending
- 2002-11-12 ES ES02789593T patent/ES2297032T3/es not_active Expired - Lifetime
- 2002-11-12 TW TW091133146A patent/TW200300680A/zh unknown
- 2002-11-12 AT AT02789593T patent/ATE383156T1/de not_active IP Right Cessation
- 2002-11-12 JP JP2003543592A patent/JP2005509002A/ja active Pending
- 2002-11-12 WO PCT/US2002/036253 patent/WO2003041705A1/en active IP Right Grant
- 2002-11-12 CA CA002466504A patent/CA2466504A1/en not_active Abandoned
- 2002-11-12 MX MXPA04004476A patent/MXPA04004476A/es active IP Right Grant
- 2002-11-12 IL IL16199102A patent/IL161991A0/xx unknown
- 2002-11-12 AR ARP020104341A patent/AR037356A1/es unknown
- 2002-11-12 KR KR1020047007335A patent/KR20050044459A/ko not_active Application Discontinuation
- 2002-11-12 BR BR0214081-0A patent/BR0214081A/pt not_active IP Right Cessation
-
2004
- 2004-05-03 ZA ZA200403328A patent/ZA200403328B/en unknown
- 2004-05-07 CO CO04042439A patent/CO5580744A2/es not_active Application Discontinuation
- 2004-06-11 NO NO20042440A patent/NO20042440L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1446118B1 (en) | 2008-01-09 |
| ATE383156T1 (de) | 2008-01-15 |
| IL161991A0 (en) | 2005-11-20 |
| EP1446118A1 (en) | 2004-08-18 |
| DE60224558T2 (de) | 2009-01-22 |
| CO5580744A2 (es) | 2005-11-30 |
| JP2005509002A (ja) | 2005-04-07 |
| WO2003041705A1 (en) | 2003-05-22 |
| DE60224558D1 (de) | 2008-02-21 |
| KR20050044459A (ko) | 2005-05-12 |
| ZA200403328B (en) | 2005-04-13 |
| ES2297032T3 (es) | 2008-05-01 |
| MXPA04004476A (es) | 2004-08-11 |
| TW200300680A (en) | 2003-06-16 |
| PL369962A1 (en) | 2005-05-02 |
| CN1615135A (zh) | 2005-05-11 |
| CA2466504A1 (en) | 2003-05-22 |
| NO20042440L (no) | 2004-08-09 |
| RU2004114552A (ru) | 2005-02-20 |
| US20030100595A1 (en) | 2003-05-29 |
| BR0214081A (pt) | 2004-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR6458A (es) | Composiciones de valdecoxib | |
| AR037356A1 (es) | Forma de dosificacion oral de una prodroga de sulfonamida | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
| ES2177346T3 (es) | Formulaciones de ranolazina de liberacion lenta. | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| SE8703034L (sv) | Oralt terapeutiskt system med systemisk verkan | |
| AR027091A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
| ES2255287T3 (es) | Composiciones para el tratamiento de la leucemia linfocitica cronica. | |
| CO5560580A2 (es) | Formulaciones de sucralosa para disumular sabores desagradables | |
| PA8542701A1 (es) | Composición parenteral reconstituible | |
| ITMI20001732A1 (it) | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti | |
| DE69731610D1 (de) | Orale verabreichung wirksamer mengen von hyaluronsäure | |
| UY27296A1 (es) | Composición farmacéutica que contiene mosaprida y pancreatina | |
| AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
| AR032151A1 (es) | Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
| CO5540323A2 (es) | Administracion oral de hormona paratiroides y calcitonina | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| MXPA06007510A (es) | Composiciones de farmaco y formas de dosis novedosas de topiramato. | |
| AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
| PE20030830A1 (es) | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| BRPI0413374A (pt) | composições para liberação de base fraca por um perìodo estendido de tempo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |